花卉;程佳伟;顾丽群;任祺;朱周;谷丽;

• 1:江苏省南通市第三人民医院皮肤性病科
• 2:江苏省南通市第一人民医院皮肤性病科

摘要(Abstract)：

目的:探讨Pirh2和p27^(kip1)在皮肤恶性黑色素瘤组织中的表达及其相关性。方法:采用免疫组织化学方法检测Pirh2与p27(kip1)在皮肤恶性黑色素瘤组织中的表达及其相关性。方法:采用免疫组织化学方法检测Pirh2与p27^(kip1)分别在45例皮肤恶性黑色素瘤标本与20例正常皮肤标本组织中的表达情况。结果:45例皮肤恶性黑色素瘤中Pirh2的阳性表达率为68.89%(31/45),p27(kip1)分别在45例皮肤恶性黑色素瘤标本与20例正常皮肤标本组织中的表达情况。结果:45例皮肤恶性黑色素瘤中Pirh2的阳性表达率为68.89%(31/45),p27^(kip1)的阳性表达率为17.78%(8/45);20例正常皮肤组织中Pirh2的阳性表达率为0%,p27(kip1)的阳性表达率为17.78%(8/45);20例正常皮肤组织中Pirh2的阳性表达率为0%,p27^(kip1)的阳性表达率为75.00%(15/20)。正常皮肤组与皮肤恶性黑色素瘤组间比较,Pirh2与p27(kip1)的阳性表达率为75.00%(15/20)。正常皮肤组与皮肤恶性黑色素瘤组间比较,Pirh2与p27^(kip1)的表达差异有统计学意义,且皮肤恶性黑色素瘤组的Pirh2与p27(kip1)的表达差异有统计学意义,且皮肤恶性黑色素瘤组的Pirh2与p27^(kip1)的表达呈负相关(P<0.01)。结论:Pirh2在皮肤恶性黑色素瘤组织中的表达增加,与p27Kip1的表达呈负相关,提示两者可能参与了皮肤黑色恶性素瘤的发生和发展。

关键词(KeyWords)： 皮肤恶性黑色素瘤;Pirh2;p27kip1;免疫组织化学法

Abstract:

Keywords:

基金项目(Foundation): 南通市科技计划项目(yyzl5013)

作者(Authors): 花卉;程佳伟;顾丽群;任祺;朱周;谷丽;

DOI: 10.16424/j.cnki.cn32-1807/r.2018.06.005

参考文献(References)：

• [1]刘宏杰.皮肤黑色素瘤6例临床浅析[J].中国全科医学:医生读者版, 2013(5):47-49.
• [2] WANG Z, YANG B, DONG L, et al. A novel oncoprotein Pirh2:rising from the shadow of Mdm2[J]. Cancer Sci,2011, 102(5):909-917.
• [3] OHTANI M, ISOZAKI H, FUJII K, et al. Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-early stage gastric carcinoma[J]. Cancer, 1999,85(8):1711-1718.
• [4] SHANG F, TAYLOR A. Ubiquitin-proteasome pathway and cellular responses to oxidative stress[J]. Free Radic Biol Med, 2011, 51(1):5-16.
• [5] PAMARTHY D, TAN M, WU M, et al. p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway[J]. Cancer Biol Ther, 2007, 6(3):360-366.
• [6]邱艳艳,董兰兰,朱果果,等.泛素连接酶Pirh2与恶性肿瘤相关性的研究进展[J].肿瘤, 2011, 4(3):369-373.
• [7] WANG L, HE G, ZHANG P, et al. Interplay be tween MDM2, MDMX, Pirh2 and COP1:the negative regulators of p53[J]. Mol Biol Rep, 2011, 38(1):229-236.
• [8] JUNG YS, LIU G, CHEN X. Pirh2 E3 ubiquitin ligase targets DNA polymerase eta for 20S proteasomal degradation[J]. Mol Cell Biol, 2010, 30(4):1041-1048.
• [9] WANG XM, YANG LY, GUO L, et al. p53-induced RING-H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection[J]. Cancer,2009, 115(19):4554-4563.
• [10] DUAN W, GAO L, DRUHAN LJ, et al. Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer[J]. J Natl Cancer Inst, 2004, 96(22):1718-1721.
• [11] JI P, GOLDIN L, REN H, et al. Skp2 contains a novel cyclin A binding domain that directly protects cyclin A from inhibition by p27Kip1[J]. J Biol Chem, 2006, 281(33):24058-24069.
• [12] HATTORI T, ISOBE T, ABE K, et al. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitorp27Kip1[J]. Cancer Res, 2007, 67(22):10789-10795.
• [13] SHIMADA M, KITAGAWA K, DOBASHI Y, et al. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers[J]. Cancer Sci, 2009, 100(5):866-872.
• [14] HUANG X, QIAN X, CHENG C, et al. Expression of Pirh2, a p27(Kip1)ubiquitin ligase, in hepatocellular carcinoma:correlation with p27(Kip1)and cell proliferation[J].Hum Pathol, 2011, 42(4):507-515.